Suppr超能文献

西那卡塞的时间治疗法对继发性甲状旁腺功能亢进大鼠的甲状旁腺增殖抑制具有显著效果。

Chronotherapy with Cinacalcet has a striking effect on inhibition of parathyroid gland proliferation in rats with secondary hyperparathyroidism.

作者信息

Egstrand Søren, Mace Maria Lerche, Morevati Marya, Engelholm Lars Henning, Thomsen Jesper Skovhus, Brüel Annemarie, Olgaard Klaus, Lewin Ewa

机构信息

Nephrological Department, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

Nephrological Department, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

出版信息

PLoS One. 2025 Jan 6;20(1):e0316675. doi: 10.1371/journal.pone.0316675. eCollection 2025.

Abstract

Secondary hyperparathyroidism (sHPT) is a significant clinical complication of CKD leading to bone abnormalities and cardiovascular disease. Current treatment based on activating the parathyroid calcium-sensing receptor (CaSR) using calcimimetics such as Cinacalcet, aims to decrease plasma PTH levels and inhibit the progression of parathyroid hyperplasia. In the present study, we found significant diurnal rhythmicity of Casr, encoding the Cinacalcet drug target in hyperplastic parathyroid glands (p = 0.006). In rats with sHPT, Cinacalcet treatment timed prior to the acrophase of Casr expression (chronotherapy: Cina1) was compared with the usual timing of treatment early in the active phase (conventional: Cina2). Without Cinacalcet treatment, induction of sHPT resulted in a significant increase in parathyroid proliferation in terms of Ki-67+ cells compared to that of control rats (p = 0.001). Conventional Cinacalcet treatment (Cina2) did not significantly reduce Ki-67 index compared to untreated rats with sHPT (p = 0.09). In contrast, chronotherapy treatment (Cina1) resulted in a marked inhibition of parathyroid proliferation by Ki-67+ cells compared to untreated rats with sHPT (p = 0.0001). We found significantly reduced parathyroid Ki-67 index using chronotherapy compared to conventional timing of Cinacalcet (Cina1 vs. Cina2: 0.92±0.14% vs. 2.46±0.37%, p = 0.006). Transcriptomic analysis showed that the reduced proliferation of Cina1 was associated with downregulation of genes involved in mitotic activity, together with an increased adaptive response of energy metabolism, as evident from upregulated pathways of Oxidative phosphorylation and TCA cycle compared to the untreated uremic group. Conclusively, it is shown that the inhibitory effect of Cinacalcet on parathyroid cell proliferation is markedly impacted by the timing of administration, suggesting a possible benefit of using chronotherapy in Cinacalcet treatment of sHPT.

摘要

继发性甲状旁腺功能亢进(sHPT)是慢性肾脏病(CKD)的一种重要临床并发症,可导致骨骼异常和心血管疾病。目前的治疗方法是使用西那卡塞等拟钙剂激活甲状旁腺钙敏感受体(CaSR),旨在降低血浆甲状旁腺激素(PTH)水平并抑制甲状旁腺增生的进展。在本研究中,我们发现增生性甲状旁腺中编码西那卡塞药物靶点的Casr存在显著的昼夜节律性(p = 0.006)。在患有sHPT的大鼠中,将西那卡塞治疗时间安排在Casr表达的高峰期之前(时间疗法:Cina1)与在活跃期早期的常规治疗时间(传统疗法:Cina2)进行比较。在未进行西那卡塞治疗的情况下,与对照大鼠相比,sHPT的诱导导致甲状旁腺增殖在Ki-67+细胞方面显著增加(p = 0.001)。与未治疗的sHPT大鼠相比,传统的西那卡塞治疗(Cina2)并未显著降低Ki-67指数(p = 0.09)。相比之下,与未治疗的sHPT大鼠相比,时间疗法治疗(Cina1)导致Ki-67+细胞对甲状旁腺增殖有明显抑制作用(p = 0.0001)。我们发现,与西那卡塞的常规给药时间相比,使用时间疗法可显著降低甲状旁腺Ki-67指数(Cina1与Cina2:0.92±0.14%对2.46±0.37%,p = 0.006)。转录组分析表明,Cina1组增殖减少与有丝分裂活性相关基因的下调有关,同时能量代谢的适应性反应增加,与未治疗的尿毒症组相比,氧化磷酸化和三羧酸循环途径上调明显。总之,研究表明西那卡塞对甲状旁腺细胞增殖的抑制作用受给药时间的显著影响,这表明在西那卡塞治疗sHPT中使用时间疗法可能有益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7223/11703009/a73e0899d54e/pone.0316675.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验